ARCHETYPE EAU NMIBC risk assessment (2021) (openEHR-EHR-CLUSTER.eau_nmibc_2021.v1)

ARCHETYPE IDopenEHR-EHR-CLUSTER.eau_nmibc_2021.v1
ConceptEAU NMIBC risk assessment (2021)
DescriptionThe European Association of Urology (EAU) 2021 risk assessment for non–muscle-invasive bladder cancer (NMIBC) stratify patients based on the prognostic factors tumour characteristics, patient age, and WHO grading systems for urothelial neoplasms.
UseUse to record each component parameter and the risk group for the EAU NMIBC risk assessment (2021), based on the WHO 2004/2016 or WHO 1973 grading systems.
PurposeTo record each component parameter and the risk group for the EAU NMIBC risk assessment (2021).
ReferencesSylvester RJ, Rodríguez O, Hernández V, Turturica D, Bauerová L, Bruins HM, et al. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. Eur Urol. 2021 Apr;79(4):480-488. doi: 10.1016/j.eururo.2020.12.033. Epub 2021 Jan 6. PubMed PMID: 33419683.

Compérat EM, Burger M, Gontero P, Mostafid AH, Palou J, Rouprêt M, et al. Grading of Urothelial Carcinoma and The New "World Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016". Eur Urol Focus. 2019 May;5(3):457-466. doi: 10.1016/j.euf.2018.01.003. Epub 2018 Jan 20. PubMed PMID: 29366854.

Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder Tumours. Eur Urol. 2016 Sep;70(1):93-105. doi: 10.1016/j.eururo.2016.02.028. PubMed PMID: 26996659.

Gontero P, Baard J, Birtle A, Compérat E, Domínguez Escrig J, Fiorini E, Liedberg F, Mariappan P, Masson-Lecomte A, Pradère B, Rai B, Seisen T, Shariat S, Teoh J, Van Rhijn B, Wood R, Xylinas E, D'Andrea D, Moschini M, Soria F, Soukup V, Čapoun O. EAU Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS). [revised 2025]. [Internet]. Arnhem, The Netherlands: EAU Guidelines Office; 2024. Available from: https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer.

EAU NMIBC Risk Calculator. In: [Internet]. Arnhem, Netherlands: European Association of Urology; 2021. Available from: https://nmibc.net.
Copyright© openEHR Foundation
AuthorsAuthor name: Silje Ljosland Bakke
Organisation: Helse Vest IKT AS
Email: silje.ljosland.bakke@helse-vest-ikt.no
Date originally authored: 2025-05-23
Other Details LanguageAuthor name: Silje Ljosland Bakke
Organisation: Helse Vest IKT AS
Email: silje.ljosland.bakke@helse-vest-ikt.no
Date originally authored: 2025-05-23
Other Details (Language Independent)
  • Licence: This work is licensed under the Creative Commons Attribution-ShareAlike 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-sa/4.0/.
  • Custodian Organisation: openEHR Foundation
  • References: Sylvester RJ, Rodríguez O, Hernández V, Turturica D, Bauerová L, Bruins HM, et al. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. Eur Urol. 2021 Apr;79(4):480-488. doi: 10.1016/j.eururo.2020.12.033. Epub 2021 Jan 6. PubMed PMID: 33419683. Compérat EM, Burger M, Gontero P, Mostafid AH, Palou J, Rouprêt M, et al. Grading of Urothelial Carcinoma and The New "World Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016". Eur Urol Focus. 2019 May;5(3):457-466. doi: 10.1016/j.euf.2018.01.003. Epub 2018 Jan 20. PubMed PMID: 29366854. Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder Tumours. Eur Urol. 2016 Sep;70(1):93-105. doi: 10.1016/j.eururo.2016.02.028. PubMed PMID: 26996659. Gontero P, Baard J, Birtle A, Compérat E, Domínguez Escrig J, Fiorini E, Liedberg F, Mariappan P, Masson-Lecomte A, Pradère B, Rai B, Seisen T, Shariat S, Teoh J, Van Rhijn B, Wood R, Xylinas E, D'Andrea D, Moschini M, Soria F, Soukup V, Čapoun O. EAU Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS). [revised 2025]. [Internet]. Arnhem, The Netherlands: EAU Guidelines Office; 2024. Available from: https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer. EAU NMIBC Risk Calculator. In: [Internet]. Arnhem, Netherlands: European Association of Urology; 2021. Available from: https://nmibc.net.
  • Original Namespace: org.openehr
  • Original Publisher: openEHR Foundation
  • Custodian Namespace: org.openehr
  • MD5-CAM-1.0.1: 3BD0B1892C41D02AA829D036A75E8718
  • Build Uid: 4afa2872-98ab-4042-bde8-e80acbd027f7
  • Revision: 1.0.0
Keywordsbladder, cancer, stratification, TURBT, non–muscle-invasive, urothelial, carcinoma, prognostic, group
Lifecyclepublished
UIDe35c36ab-d159-4110-af04-66d4fb90bab9
Language useden
Citeable Identifier1013.1.8076
Revision Number1.0.0
items
AgeAge:
  • ≤ 70 years
  • > 70 years
Tumor statusTumor status:
  • Primary
  • Recurrent
Number of tumorsNumber of tumors:
  • Single
  • Multiple
Maximum tumor diameterMaximum tumor diameter:
  • < 3 cm
  • ≥ 3 cm
StageStage:
  • Ta [Non-invasive papillary tumor confined to the urothelium.]
  • T1 [Tumor invasion into the lamina propria, sparing the muscularis propria.]
Concomitant CISConcomitant CIS:
  • No
  • Yes
WHO grade 2004/2016WHO grade 2004/2016: Only one of the two classification systems (WHO 1973 or WHO 2004/2016) should be used at one time.
  • LMP-LG [Non-invasive papillary tumours with minimal atypia and orderly cells.]
  • HG [Tumours with significant architectural and nuclear atypia, frequent mitoses, and loss of normal cell structure.]
WHO grade 1973WHO grade 1973: Only one of the two classification systems (WHO 1973 or WHO 2004/2016) should be used at one time.
  • G1 [Well-differentiated tumours with minimal atypia and orderly architecture.]
  • G2 [Moderately differentiated tumours with intermediate atypia and architectural irregularities.]
  • G3 [Poorly differentiated tumours with marked atypia, disorganized structure, and frequent mitoses. ]
Risk groupRisk group: Risk of recurrence based on the component parameters.
Additional clinical risk factors are: age > 70; multiple papillary tumours; and tumour diameter > 3 cm.
  • Low Risk [A primary, single, TaT1 LG/G1 tumour < 3 cm in diameter without CIS in a patient ≤ 70 years OR A primary Ta LG/G1 tumour without CIS with at most ONE of the additional clinical risk factors.]
  • Intermediate Risk [Patients without CIS who are not included in either the low-, high-, or very high-risk groups.]
  • High Risk [All T1 HG/G3 without CIS, EXCEPT those included in the very high-risk group OR All CIS patients, EXCEPT those included in the very high-risk group OR Ta LG/G2 or T1G1, no CIS with all 3 risk factors OR Ta HG/G3 or T1 LG, no CIS with at least 2 risk factors OR T1G2 no CIS with at least 1 risk factor.]
  • Very High Risk [Ta HG/G3 and CIS with all 3 risk factors OR T1G2 and CIS with at least 2 risk factors OR T1 HG/G3 and CIS with at least 1 risk factor OR T1 HG/G3 no CIS with all 3 risk factors.]
Other contributorsVebjørn Arntzen, Oslo University Hospital, Norway
Silje Ljosland Bakke, Helse Vest IKT AS, Norway (openEHR Editor)
SB Bhattacharyya, Bhattacharyyas Clinical Records Research & Informatics LLP, India
Tara Bonet Chinillach, Catalan Health Service, Spain
Grete Hovde Bøe, Sykehuspartner HF, Norway
Aydin Dadfar, Oslo Universitetssykehus, Norway
Aleksander Furnes, Helse Nord IKT, Norway
Kristina Førde, Helse Bergen, Norway
Gigja Gudbrandsdottir, Helse Bergen, Norway
Joachim Hansen, UNN, Norway
Evelyn Hovenga, EJSH Consulting, Australia
Elin Kristiansen, Sykehuspartner HF, Norway
Heather Leslie, Atomica Informatics, Australia
Ian McNicoll, freshEHR Clinical Informatics, United Kingdom
Martin Milde, Helse Vest IKT, Norway
Olha Nikolaieva, University Hospital Basel, Switzerland
Terje Nordberg, Helse Bergen, Norway
Mikael Nyström, Cambio Healthcare Systems AB, Sweden
Ruben Rognmo, Helse Nord IKT, Norway
Lena Schell-Majoor, University of Oldenburg, Germany
Marte Vassli Gullesen, HNIKT, Norway
Linn Wiker Røstengen, OUS, Norway
Translators
  • Norwegian Bokmål: Grete Hovde Bøe, Silje Ljosland Bakke, Sykehuspartner HF, Helse Vest IKT AS, grete.kristin.hovde.boe@sykehuspartner.no, silje.ljosland.bakke@helse-vest-ikt.no
    Other Contributors: Elin Kristiansen, Sykehuspartner, Norway; Aleksander Spikkerud Furnes, Helse Nord IKT, Norway; Silje Ljosland Bakke, Helse Vest IKT AS